1. Home
  2. EIX vs VTRS Comparison

EIX vs VTRS Comparison

Compare EIX & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edison International

EIX

Edison International

N/A

Current Price

$59.93

Market Cap

22.6B

Sector

Utilities

ML Signal

N/A

Logo Viatris Inc.

VTRS

Viatris Inc.

N/A

Current Price

$21.05

Market Cap

21.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EIX
VTRS
Founded
1886
1961
Country
United States
United States
Employees
N/A
30000
Industry
Electric Utilities: Central
Medicinal Chemicals and Botanical Products
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.6B
21.0B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
EIX
VTRS
Price
$59.93
$21.05
Analyst Decision
Hold
Buy
Analyst Count
17
12
Target Price
★ $63.03
$21.00
AVG Volume (30 Days)
3.8M
★ 8.6M
Earning Date
10-29-2026
11-05-2026
Dividend Yield
★ 5.83%
2.30%
EPS Growth
★ 248.94
N/A
EPS
★ 4.62
N/A
Revenue
★ $19,317,000,000.00
$14,299,900,000.00
Revenue This Year
N/A
$3.53
Revenue Next Year
$2.67
$3.69
P/E Ratio
$13.04
★ N/A
Revenue Growth
★ 9.76
N/A
52 Week Low
$51.10
$10.15
52 Week High
$81.62
$20.84

Technical Indicators

Market Signals
Indicator
EIX
VTRS
Relative Strength Index (RSI) 59.10 75.31
Support Level $51.71 $16.02
Resistance Level $75.73 N/A
Average True Range (ATR) 1.30 0.57
MACD 0.20 0.21
Stochastic Oscillator 58.11 98.45

Price Performance

Historical Comparison
EIX
VTRS

About EIX Edison International

Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.

Share on Social Networks: